drugset / Trial / NCT00482235

A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)

NCT00482235 ↗

Phase 2 Completed 45 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

A study to test the effect of MK0359 in lessening the symptoms of COPD as compared to salmeterol and placebo.

Timeline

Start
2002-12
Primary completion
2003-04
Completion
2003-04

Drugs

EvaluationDrugModalityDoseRoute
Subject MK0359 Unknown 15 mg Oral